FF
BPMC

FourThought Financial’s Blueprint Medicines BPMC Stock Holding History

FourThought Financial’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-305
Closed -$19K – 1478
2022
Q1 		$19K Hold
305
– – ﹤0.01% 911
2021
Q4 		$33K Hold
305
– – ﹤0.01% 796
2021
Q3 		$31K Hold
305
– – ﹤0.01% 835
2021
Q2 		$26K Sell
305
-12
-4% -$1.1K ﹤0.01% 880
2021
Q1 		$30K Sell
317
-16
-5% -$1.6K ﹤0.01% 814
2020
Q4 		$37K Buy
+333
New +$35.1K 0.01% 732

Other funds holding BPMC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

FourThought Financial's BPMC Position: Q2 2022 in Review

FourThought Financial sold out of Blueprint Medicines (BPMC) in Q2 2022, closing a stake of 305 shares — an estimated $19K sold.

FourThought Financial first reported a position in BPMC in Q4 2020 and held it in 6 quarters. The position peaked at $37K in Q4 2020. 237 funds tracked by Wall St. Rank hold BPMC as of Q2 2022.

  • FourThought Financial reported no remaining Blueprint Medicines position as of Q2 2022 after selling out during the quarter.
  • FourThought Financial sold 305 Blueprint Medicines shares in Q2 2022, an estimated $19K.
  • FourThought Financial first reported a position in Blueprint Medicines in Q4 2020 and held it in 6 quarters.
  • FourThought Financial's Blueprint Medicines position peaked at $37K in Q4 2020.
  • 237 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2022.

Based on FourThought Financial's 13F filing for Q2 2022, filed 12 Aug 2022.